BCL2 interacting protein 3 likeGenealiases: BNIP3a · NIP3L · NIX
Q-omics provides the consensus-scored BNIP3L profile across patient tissues and cancer cell-line models. BNIP3L expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, BNIP3L is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, BNIP3L RNA expression shows 18,976 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, KIRC, and ACC as cancer lineages where BNIP3L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BNIP3L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BNIP3L survival associations across molecular data types. BNIP3L RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BNIP3L RNA expression–survival associations across cancer types. High BNIP3L expression shows unfavorable associations in KICH, MESO, STAD, BLCA and LIHC, but favorable associations in KIRC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for BNIP3L RNA expression.
This table summarizes BNIP3L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for BNIP3L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BNIP3L shows lower tumor expression in KICH, THCA and BRCA and higher tumor expression in KIRC, HNSC and KIRP. The KIRC box plot shows higher BNIP3L RNA expression in tumor versus normal tissue (log2 FC = +1.270, t-test p < 0.001).
This table shows molecular features associated with BNIP3L in patient tissues and cancer cell lines. In patient samples, BNIP3L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BNIP3L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
